Cabrera LJO, Ricardo SYM, Noguera BCB

Language: Spanish
References: 26
Page: 1-13
PDF size: 300.65 Kb.

ABSTRACT

Introduction: nonalcoholic fatty liver disease is the most common cause of chronic liver disease, half of these patients develop nonalcoholic steatohepatitis.
Objective: to determine by using anthropometrics, clinics and biochemical factors a discriminant function and identify the most useful ones to predict liver fibrosis in patient with nonalcoholic steatohepatitis.
Methods: a case control study in 62 patients who underwent liver biopsy at Gastroenterology Service, between July 2005 to November 2012 at Carlos Manuel de Céspedes Hospital in Bayamo was carried out.
Results: 21 patients (33.8%) presented liver fibrosis, the mean values of waist circumference, body mass index, cholesterol, triglycerides, C reactive protein and blood glucose was significant higher (p‹0.00) in patient who developed liver fibrosis, the proportion of diabetes and hypertension was higher too (p‹0.000), nevertheless the transaminases values and the age do not discriminated between both groups and gender was not associated with fibrosis.
Conclusions: the discriminant equation calculated with blood glucose, waist circumference, C reactive protein and triglycerides classified correctly more than two third part of the patient with fibrosis and the diagnostic performance was better than BARD index.

REFERENCES

1. Ampuero J, Romero Gómez M. Influencia de la enfermedad por hígado graso no alcohólico en la enfermedad cardiovascular. Gastroenterol Hepatol. 2012[citado 10 ene 2013]; 35(8):585-93.Disponible en: http://zl.elsevier.es/es/revista/gastroenterologia-hepatologia-14/influencia-enfermedad-higado-graso-no-alcoholico-enfermedad-90154578-progresos-hepatologia-2012

2. Neuschwander Tetri BA, Caldwell S. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. J Hepatol. 2003[citado 10 ene 2013]; 37(5):1202-19. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/12717402

3. James FW, Day CP. Non alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol. 1998[citado 10 ene 2013]; 29(3):495-550.Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/9765002

4. Shamseddenn H, Getty JZ, Hamdallah IN. Epidemiology and economic impact of obesity and type diabetes. Surg Clin North Am. 2011[citado 10 ene 2013]; 91(6): 1163-72. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22054146

5. Tarantino G. Noninvasive investigations for nonalcoholic fatty liver disease and liver fibrosis. World J Gastroenterol. 2010[citado 10 ene 2013]; 16 (38): 4784-91. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20939106

6. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010[citado 10 ene 2013]; 363: 1341-50. Disponible en: http://www.nejm.org/doi/full/10.1056/NEJMra0912063

7. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, et al. Nonalcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011 [citado 10 ene 2013]; 343: 6891. Disponible en: http://www.bmj.com/content/343/bmj.d6891

8. Bhala N, Angulo P, Poorten D, Lee E, Hui JM, Saracco G, et al. The Natural History of Nonalcoholic Fatty Liver Disease with advance fibrosis or cirrhosis: An International Collaborative Study. J Hepatol. 2011[citado 10 ene 2013]; 54(4): 1208-16. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21688282

9. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003[citado 10 ene 2013]; 38(6): 1449-57. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/14647056

10. Brunt EM, Janney CJ, Di Bisceglie AM. Non alcoholic steatohepatitis: A proposal for grading and staging the histologic lesions. Am J Gastroenterol. 1999[citado 10 ene 2013]; 94(9):2467–74. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/10484010

11. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Geneva: WHO; 2006.

12. Cuba. Ministerio de Salud Pública. Guía Cubana de diagnóstico y tratamiento de la hipertensión arterial. La Habana: Editorial Ciencias Médicas; 2008.

13. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwandet Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008[citado 10 ene 2013]; 57(10):1441-47. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18390575

14. Kleiner DE, Bondini S, Goodman Z. Pathologic assessment of non-alcoholic fatty liver disease. Clin Liver Dis. 2007[citado 10 ene 2013]; 11(1):17–23. Disponible en:http://www.ncbi.nlm.nih.gov/pubmed/17544969

15. Hui AY, Wong VW, Chan HL. Histological progression of non alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther. 2005[citado 10 ene 2013]; 21(4): 407–13. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15709991

16. Kagansky N, Levy S, Keter D. Non alcoholic fatty liver disease a common and benign finding in octogenarian patients. Liver Int. 2004[citado 10 ene 2013]; 24(6): 588–94. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15566509

17. Chen ZW, Chen LY, Dai HL, Chen JH, Fang LZ. Relationship between alanine aminotransferase levels and metabolic syndrome in non alcoholic fatty liver disease. J Zhejiang Univ Sci B. 2008[citado 10 ene 2013]; 9(8): 616–22. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18763311

18. Marchesini G, Bugianesi E, Forlani G, Marzocchi R, Zannoni Ch, Vanni E, et al. Non alcoholic steatohepatitis in patients cared in metabolic units. Diabetes Research and Clinical Practice. 2004[citado 10 ene 2013]; 63(2): 143-51. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/14739055

19. Prashanth M, Ganesh HK, Vima MV. Prevalence of non alcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India. 2009[citado 10 ene 2013]; 57: 205–10. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19588648

20. Balkau B, Lange C, Vol S, Fumeron F, Bonnet F. Nesienarceh R. Incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. Gastroenterol. 2010[citado 10 ene 2013]; 10:56-65. Disponible en: http://www.biomedcentral.com/1471-230X/10/56

21. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non alcoholic fatty liver disease and non alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011[citado 10 ene 2013]; 33(5): 525–40. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21198708

22. Raszeja J, Szymanik B, Lawniczak M, Kajor M, Chwist A, Milkiewicz P, et al. Validation of BARD scoring system in Polish patient with non alcoholic fatty liver disease. Gastroenterol. 2010[citado 10 ene 2013]; 10:67. Disponible en: http://www.biomedcentral.com/1471-230X/10/67

23. Grigorescu M, Crisan D, Radu C, Grigorescu D, Sparchez Z, Serban A. A novel pathophysiological based panel of biomarkers for the diagnosis of non alcoholic steatohepatitis. J Physiol pharmacol. 2012[citado 10 ene 2013]; 63(4): 347-53. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23070083

24. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. J Hepatol. 2003[citado 10 ene 2013]; 38(2):518-26. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/12883497

25. Amato M, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, et al. Visceral adipose index. A reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010[citado 10 ene 2013]; 33(4):920–22. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20067971

26. Zimmermann E, Anty R, Tordjman J, Verrijken A, Gual P, Tran A, et al. Creactive protein level in relation to varios features in non alcoholic fatty liver disease among obese patient. J Hepatol. 2011[citado 10 ene 2013]; 55(3): 660–65. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21238518